Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAt 5mg, Mounjaro is the first full therapeutic step — the point where many people begin to see meaningful appetite change after four weeks on the 2.5mg starter dose. Reviews of Mounjaro 5mg consistently describe a noticeable shift in hunger, though how pronounced that shift feels varies between individuals. This is a prescription-only medicine; a prescriber assesses whether it's clinically appropriate for you before anything is dispensed. What follows draws on the clinical trial data, the NHS prescribing record and the patterns our clinical team hears most often.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
If you're reading 5mg Mounjaro reviews, you're probably at one of two crossroads. Either you've just been moved up from 2.5mg and you're trying to calibrate your expectations, how much different should 5mg feel, and when?, or you're still weighing up treatment and want to know what the lived experience looks like beyond the clinical trial averages.
Both are reasonable things to want to know. The honest answer to the first is: for many people, 5mg is where the medicine stops feeling like an adjustment and starts feeling like it's working. Appetite changes become more consistent. The urge to eat between meals fades. Portion sizes that would previously have felt inadequate start to feel right. None of that is guaranteed (bodies vary and prescribers track this at every review) but it's the pattern reported frequently enough to be worth naming plainly.
For a broader picture of how this dose sits within the full 5mg arc, our Mounjaro 5mg overview page covers the prescribing context in more detail. And if you're still deciding whether treatment is the right move, the weight-loss treatment overview is a good starting point.
The large SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across tirzepatide doses and placebo over 72 weeks. Participants didn't begin at the highest dose, they titrated through exactly the schedule that includes 5mg. This matters because the trial's weight-loss figures (around 20–21% at 15mg) reflect a gradual process, not a result achieved overnight at a single dose.
At 5mg specifically, participants typically spend four weeks before a prescriber reviews whether to increase. During that window, the most commonly reported changes are reduced hunger, altered food preferences and a tendency to feel full sooner. GI effects (nausea particularly) often lessen compared with the first few weeks on 2.5mg, though some people experience a brief uptick when they move up. The first-dose side-effects page explains the pattern in detail.
Weight change at 5mg alone isn't the measure of whether treatment is working. The titration exists because the medicine's job at each dose is partly to let your system adapt. A modest loss at 5mg doesn't mean higher doses won't be more effective, the evidence trajectory points the other way. The NHS tirzepatide page outlines what to expect through the schedule in plain language.
Nausea is the most cited experience in real-world accounts of Mounjaro 5mg, followed by constipation, occasional loose stools and a sense of feeling full uncomfortably quickly if meals are too large. These are the same effects the clinical trials recorded, GI-driven, generally mild to moderate, most noticeable in the first one to two weeks after a dose change.
A few practical details that come up repeatedly in reviews and in questions to our clinical team: eating smaller portions more slowly makes nausea significantly more manageable. Very fatty or heavy meals tend to amplify discomfort at this dose. Staying well hydrated matters more than people expect, partly because reduced appetite can mean reduced fluid intake too.
Serious side effects are uncommon but not theoretical. Severe stomach pain that radiates to the back (with or without vomiting and not settling quickly) warrants urgent medical attention; the MHRA has specifically highlighted acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines. Report any unexpected effects via the Yellow Card scheme. Your prescriber should always be your first call if something feels wrong.
Online reviews of Mounjaro 5mg are genuine and often detailed, but they carry a selection bias worth keeping in mind. People experiencing dramatic early results or difficult side effects are more likely to post than people having a quietly effective experience. Neither extreme is representative of the average.
The more useful signal in reviews is consistency of pattern rather than headline numbers. When many independent accounts describe the same appetite shift, the same timing of GI effects or the same improvement at week two or three, that aligns with what the clinical evidence predicts and what the weight-loss specific 5mg review roundup also finds. If you want to see how people describe the step just before this one, the Mounjaro 2.5mg reviews offer a useful point of comparison, and for those further along the titration, reading what people report at 10mg can help set longer-term expectations.
For context on how 5mg sits within the wider cost-to-outcome picture, the Mounjaro pricing page covers what a private prescription typically includes and how to think about value beyond the per-pen figure. The starting point, though, is a clinical assessment. If Mounjaro is suitable for you and your prescriber approves treatment, the pen itself arrives from our GPhC-registered pharmacy via DPD the next working day, in plain, unmarked packaging, tracked to your door. No GP referral required; a free consultation with our clinical team is where that process begins.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.